Heart Failure Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight

Heart Failure Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight https://www.delveinsight.com/sample-request/heart-failure-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav https://www.delveinsight.com/report-store/heart-failure-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav https://www.delveinsight.com/sample-request/heart-failure-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav https://www.delveinsight.com/sample-request/heart-failure-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav https://www.delveinsight.com/consulting-services (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Heart Failure pipeline constitutes 70+ key companies continuously working towards developing 75+ Heart Failure treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight."Heart Failure Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Heart Failure Market.The Heart Failure Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.Some of the key takeaways from the Heart Failure Pipeline Report:• Companies across the globe are diligently working toward developing novel Heart Failure treatment therapies with a considerable amount of success over the years.• Heart Failure companies working in the treatment market are Tenaya Therapeutics, Athersys, TransThera Biosciences, SalubrisBio, Ionis Pharmaceuticals, Arena Pharmaceuticals, Palatin Technologies, Bayer HealthCare, Eli Lilly and Company, and others, are developing therapies for the Heart Failure treatment• Emerging Heart Failure therapies in the different phases of clinical trials are- TN-301, Invimestrocel, TT-00920, JK-07, IONIS AGT LRx, APD418, PL-3994, Finerenone, Tirzepatide, and others are expected to have a significant impact on the Heart Failure market in the coming years.• In September 2206, The U.S. Food and Drug Administration (FDA) has granted De Novo authorization to Powerful Medical's Queen of Hearts, an AI-based model designed to detect acute coronary syndrome (ACS) through electrocardiogram (ECG) analysis. The technology aims to support the early identification of patients with suspected ACS who may benefit from timely cardiology consultation and early cardiac catheterization. While ACS is commonly associated with heart attacks, the term also includes conditions such as unstable angina, which can indicate an increased risk of an imminent heart attack.• In November 2025, Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences firm focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for its patent application titled "Cannabidal Compositions for Use in Treating Heart Conditions." Once granted, this patent will provide broad intellectual property protection for the use of CardiolRxTM and CRD-38 in treating or preventing a wide array of cardiac conditions, including heart failure, myocarditis, acute pericarditis, inflammatory cardiomyopathy, cardiac toxicity from cancer therapies, and atherosclerosis, extending through October 2040.• In May 2025, BioCardia announced the enrollment of the first participant in its randomized, double-blind, placebo-controlled Phase III CardiAMP HF II trial, evaluating its autologous cell therapy for ischemic heart failure. The enrollment occurred at BayCare Morton Plant Hospital in Clearwater, Florida, U.S. The 250-patient, multicenter study is designed to assess a single administration of CardiAMP therapy in patients with ischemic HF with reduced ejection fraction (HFrEF), who are on guideline-directed medical therapy and have elevated N-terminal pro B-type natriuretic peptide (NT-proBNP) levels.• In May 2025, Medera Inc., a clinical-stage biopharmaceutical company developing next-generation therapies for cardiovascular diseases, announced that data from its First-In-Human Phase 1/2a MUSIC-HFpEF trial of the adeno-associated virus-based gene therapy candidate SRD-002 for heart failure with preserved ejection fraction (HFpEF) will be presented at the upcoming Heart Failure 2025 Congress.• In April 2025, Emory University School of Medicine in the U.S. began enrolling participants for BioCardia's Phase III CardiAMP HF II trial, evaluating the CardiAMP Cell Therapy Product for the treatment of ischemic heart failure. The study is focused on patients with reduced ejection fraction and elevated cardiac stress markers.• In April 2025, An independent Data Safety Monitoring Board (DSMB) has recommended that BioCardia continue its Phase I/II CardiALLO-HF trial as planned. This decision follows a review of 30-day safety data from participants in the trial's low-dose 20 million cell cohort, which showed no treatment-related adverse cardiac events or immune responses to the implanted allogeneic cells. With DSMB approval, BioCardia plans to expand the study by enrolling 39 additional participants across the U.S. The trial is designed to evaluate the safety and efficacy of mesenchymal stromal/stem cells (MSCs) in treating heart failure.Heart Failure OverviewHeart failure, sometimes called congestive heart failure, is a progressive, chronic illness in which the heart muscle cannot pump enough blood to meet the body's oxygen and blood requirements. Both the left and right sides of your heart, or both at once, may be affected by heart failure.Get a Free Sample PDF Report to know more about Heart Failure Pipeline Therapeutic Assessment-Emerging Heart Failure Drugs Under Different Phases of Clinical Development Include:• TN-301: Tenaya Therapeutics• Invimestrocel: Athersys• TT-00920: TransThera Biosciences• JK-07: SalubrisBio• IONIS AGT LRx: Ionis Pharmaceuticals• APD418: Arena Pharmaceuticals• PL-3994: Palatin Technologies• Finerenone: Bayer HealthCare Pharmaceuticals• Tirzepatide: Eli Lilly and CompanyHeart Failure Route of AdministrationHeart Failure pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as• Intra-articular• Intraocular• Intrathecal• Intravenous• Ophthalmic• Oral• Parenteral• Subcutaneous• Topical• TransdermalHeart Failure Molecule TypeHeart Failure Products have been categorized under various Molecule types, such as• Oligonucleotide• Peptide• Small moleculeHeart Failure Pipeline Therapeutics Assessment• Heart Failure Assessment by Product Type• Heart Failure By Stage and Product Type• Heart Failure Assessment by Route of Administration• Heart Failure By Stage and Route of Administration• Heart Failure Assessment by Molecule Type• Heart Failure by Stage and Molecule TypeDelveInsight's Heart Failure Report covers around 75+ products under different phases of clinical development like• Late-stage products (Phase III)• Mid-stage products (Phase II)• Early-stage product (Phase I)• Pre-clinical and Discovery stage candidates• Discontinued & Inactive candidates• Route of AdministrationFurther Heart Failure product details are provided in the report. Download the Heart Failure pipeline report to learn more about the emerging Heart Failure therapiesSome of the key companies in the Heart Failure Therapeutics Market include:Key companies developing therapies for Heart Failure are - Abbott Laboratories, Berlin Heart GmbH, Biotronik SE & Co. KG, Boston Scientific Corporation, Jarvik Heart Inc., Lepu Medical Technology (Beijing)Co.,Ltd., Magenta Medical Ltd, MEDICO S.R.L., Medtronic PLC, Oscor, Inc., OSYPKA MEDICAL, Shree Pacetronix Ltd, and others.Heart Failure Pipeline Analysis:The Heart Failure pipeline report provides insights into• The report provides detailed insights about companies that are developing therapies for the treatment of Heart Failure with aggregate therapies developed by each company for the same.• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Heart Failure Treatment.• Heart Failure key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.• Heart Failure Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Heart Failure market.The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.Download Sample PDF Report to know more about Heart Failure drugs and therapiesHeart Failure Pipeline Market Drivers• Alongside these drug launches, a new therapeutic strategy is being explored, prevalence of chronic heart failure on the rise, strong collaboration between main stakeholders of therapeutic innovation: scientific community, industry and regulatory agencies are some of the important factors that are fueling the Heart Failure Market.Heart Failure Pipeline Market Barriers• However, true surrogate marker for mortality in heart failure (HF) remains elusive, high cost of approved therapies, transition of a clinical HFrEF project from one stage of development to the next is still associated with considerable development risk and other factors are creating obstacles in the Heart Failure Market growth.Scope of Heart Failure Pipeline Drug Insight• Coverage: Global• Key Heart Failure Companies: Tenaya Therapeutics, Athersys, TransThera Biosciences, SalubrisBio, Ionis Pharmaceuticals, Arena Pharmaceuticals, Palatin Technologies, Bayer HealthCare, Eli Lilly and Company, and others• Key Heart Failure Therapies: TN-301, Invimestrocel, TT-00920, JK-07, IONIS AGT LRx, APD418, PL-3994, Finerenone, Tirzepatide, and others• Heart Failure Therapeutic Assessment: Heart Failure current marketed and Heart Failure emerging therapies• Heart Failure Market Dynamics: Heart Failure market drivers and Heart Failure market barriersContact Us:Gaurav Boragbora@delveinsight.com+14699457679Healthcare ConsultingAbout DelveInsightDelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.